XML 53 R43.htm IDEA: XBRL DOCUMENT v3.22.2.2
Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives - Schedule of Acquisitions and Cost-Reduction/Productivity Initiatives (Detail) - USD ($)
$ in Millions
3 Months Ended 9 Months Ended
Mar. 11, 2022
Oct. 02, 2022
Apr. 03, 2022
Oct. 03, 2021
Oct. 02, 2022
Oct. 03, 2021
Restructuring charges/(credits):            
Employee terminations   $ 158   $ 630 $ 293 $ 649
Asset impairments   17   10 44 7
Exit costs/(credits)   2   3 31 0
Restructuring charges/(credits) [1]   177   643 368 656
Transaction costs [2]   0   0 42 0
Integration costs and other [3]   22   3 170 11
Restructuring charges and certain acquisition-related costs   199   646 580 667
Additional depreciation––asset restructuring [4]   7   27 22 76
Implementation costs [5]   150   151 384 316
Total costs associated with acquisitions and cost-reduction/productivity initiatives   357   760 982 1,008
Biopharma [Member]            
Restructuring charges/(credits):            
Restructuring charges/(credits)   62   616 108 617
Other (income)/deductions––net [Member]            
Restructuring charges/(credits):            
Net periodic benefit costs/(credits) recorded in Other (income)/deductions––net   0   (63) (5) (51)
Cost of sales [Member]            
Restructuring charges/(credits):            
Additional depreciation––asset restructuring [4]   7   19 22 53
Implementation costs [5]   14   8 40 29
Selling, informational and administrative expenses [Member]            
Restructuring charges/(credits):            
Additional depreciation––asset restructuring [4]   1   8 1 23
Implementation costs [5]   136   142 344 287
Research and Development Expense [Member]            
Restructuring charges/(credits):            
Implementation costs [5]   $ 0   $ 0 $ 0 $ 1
Restructuring Charges And Acquisition-Related Costs [Member] | Arena [Member]            
Restructuring charges/(credits):            
Post closing compensation expense $ 138   $ 138      
[1] Primarily represents cost reduction initiatives. Restructuring charges/(credits) associated with Biopharma: charges of $62 million and $108 million for the three and nine months ended October 2, 2022, respectively, and charges of $616 million and $617 million for the three and nine months ended October 3, 2021, respectively.
[2] Represents external costs for banking, legal, accounting and other similar services.
[3] Represents external, incremental costs directly related to integrating acquired businesses, such as expenditures for consulting and the integration of systems and processes, and certain other qualifying costs. In the three and nine months ended October 2, 2022, integration costs and other were mostly related to our acquisition of Arena, including $138 million in payments to Arena employees in the first quarter of 2022 for the fair value of previously unvested long-term incentive awards. See Note 2A.
[4] Represents the impact of changes in the estimated useful lives of assets involved in restructuring actions.
[5] Represents external, incremental costs directly related to implementing our non-acquisition-related cost-reduction/productivity initiatives.